Mallinckrodt Names Christiana Stamoulis as President and Chief Financial Officer
Mallinckrodt (MNK) has appointed Christiana Stamoulis as President and Chief Financial Officer, effective September 22, 2025. Stamoulis, currently EVP and CFO at Incyte, will succeed Bryan Reasons, who is departing to pursue other opportunities.
With approximately 30 years of biotechnology industry experience, Stamoulis brings extensive expertise in strategy, finance, and corporate development. Her appointment follows Mallinckrodt's recent merger with Endo, marking a significant transformation period for the company. In her new role, she will oversee the finance organization and lead corporate development initiatives.
Prior to Incyte, Stamoulis held leadership positions at Unum Therapeutics, Vertex Pharmaceuticals, and served as Managing Director at Citigroup's Investment Banking division. She holds two BS degrees and an MBA from MIT.
Mallinckrodt (MNK) ha nominato Christiana Stamoulis come Presidente e Chief Financial Officer, con effetto dal 22 settembre 2025. Stamoulis, attualmente EVP e CFO presso Incyte, succederà a Bryan Reasons, che lascerà l'incarico per intraprendere nuove opportunità.
Con circa 30 anni di esperienza nell'industria biotecnologica, Stamoulis apporta una vasta competenza in strategia, finanza e sviluppo aziendale. La sua nomina segue la recente fusione di Mallinckrodt con Endo, segnando un periodo di grande trasformazione per l'azienda. Nel suo nuovo ruolo, supervisionerà l'organizzazione finanziaria e guiderà le iniziative di sviluppo aziendale.
Prima di Incyte, Stamoulis ha ricoperto ruoli di leadership presso Unum Therapeutics, Vertex Pharmaceuticals e ha lavorato come Managing Director nella divisione Investment Banking di Citigroup. È in possesso di due lauree triennali e di un MBA conseguito al MIT.
Mallinckrodt (MNK) ha designado a Christiana Stamoulis como Presidenta y Directora Financiera, con efecto a partir del 22 de septiembre de 2025. Stamoulis, actualmente EVP y CFO en Incyte, sucederá a Bryan Reasons, quien dejará el cargo para buscar otras oportunidades.
Con aproximadamente 30 años de experiencia en la industria biotecnológica, Stamoulis aporta una amplia experiencia en estrategia, finanzas y desarrollo corporativo. Su nombramiento sigue a la reciente fusión de Mallinckrodt con Endo, marcando un periodo significativo de transformación para la empresa. En su nuevo puesto, supervisará la organización financiera y liderará las iniciativas de desarrollo corporativo.
Antes de Incyte, Stamoulis ocupó cargos de liderazgo en Unum Therapeutics, Vertex Pharmaceuticals y fue Directora General en la división de Banca de Inversión de Citigroup. Posee dos títulos de licenciatura y un MBA del MIT.
Mallinckrodt (MNK)는 Christiana Stamoulis를 2025년 9월 22일부로 사장 겸 최고재무책임자(CFO)로 임명했습니다. 현재 Incyte의 EVP 겸 CFO인 Stamoulis는 다른 기회를 찾아 떠나는 Bryan Reasons의 후임입니다.
생명공학 산업에서 약 30년의 경력을 가진 Stamoulis는 전략, 재무 및 기업 개발 분야에서 폭넓은 전문성을 갖추고 있습니다. 그녀의 임명은 Mallinckrodt가 최근 Endo와 합병한 후 회사의 중요한 변혁기를 맞이한 시점에 이루어졌습니다. 새 역할에서 그녀는 재무 조직을 총괄하고 기업 개발 이니셔티브를 주도할 예정입니다.
Incyte 이전에는 Unum Therapeutics, Vertex Pharmaceuticals에서 리더십 직책을 맡았으며 Citigroup 투자은행 부서에서 전무이사로 근무했습니다. MIT에서 두 개의 학사 학위와 MBA를 취득했습니다.
Mallinckrodt (MNK) a nommé Christiana Stamoulis en tant que Présidente et Directrice Financière, à compter du 22 septembre 2025. Stamoulis, actuellement EVP et CFO chez Incyte, succédera à Bryan Reasons, qui quitte ses fonctions pour poursuivre d'autres opportunités.
Avec environ 30 ans d'expérience dans l'industrie biotechnologique, Stamoulis apporte une expertise approfondie en stratégie, finance et développement corporatif. Sa nomination intervient après la récente fusion de Mallinckrodt avec Endo, marquant une période de transformation importante pour l'entreprise. Dans ses nouvelles fonctions, elle supervisera l'organisation financière et dirigera les initiatives de développement corporatif.
Avant Incyte, Stamoulis a occupé des postes de direction chez Unum Therapeutics, Vertex Pharmaceuticals et a été Managing Director dans la division banque d'investissement de Citigroup. Elle détient deux licences et un MBA du MIT.
Mallinckrodt (MNK) hat Christiana Stamoulis mit Wirkung zum 22. September 2025 zur Präsidentin und Chief Financial Officer ernannt. Stamoulis, derzeit EVP und CFO bei Incyte, wird Bryan Reasons nachfolgen, der das Unternehmen verlässt, um neue Möglichkeiten zu verfolgen.
Mit etwa 30 Jahren Erfahrung in der Biotechnologiebranche bringt Stamoulis umfassende Expertise in Strategie, Finanzen und Unternehmensentwicklung mit. Ihre Ernennung folgt auf die kürzliche Fusion von Mallinckrodt mit Endo und markiert eine bedeutende Transformationsphase für das Unternehmen. In ihrer neuen Rolle wird sie die Finanzorganisation leiten und Initiativen zur Unternehmensentwicklung vorantreiben.
Vor Incyte hatte Stamoulis Führungspositionen bei Unum Therapeutics, Vertex Pharmaceuticals inne und war Managing Director in der Investmentbanking-Abteilung von Citigroup. Sie besitzt zwei Bachelorabschlüsse und einen MBA vom MIT.
- Strategic appointment of seasoned executive with 30 years of biotech industry experience
- Addition of strong M&A and strategic partnership expertise through new CFO
- Recent completion of merger with Endo strengthens company's market position
- Departure of current CFO Bryan Reasons creates potential transition risks
Insights
Stamoulis brings M&A expertise to Mallinckrodt at critical post-merger phase; appointment signals focus on strategic partnerships and corporate development.
Mallinckrodt's appointment of Christiana Stamoulis as President and CFO represents a strategic leadership enhancement at a pivotal transformation point. The timing is particularly significant, coming immediately after Mallinckrodt's merger with Endo, creating what appears to be a substantially transformed pharmaceutical entity.
Stamoulis brings exceptional credentials to this dual leadership role. Her approximately 30 years of biotechnology industry experience, particularly her background in corporate development at Incyte and Vertex Pharmaceuticals, positions her ideally to drive Mallinckrodt's strategic initiatives. Her investment banking experience at Citigroup and Goldman Sachs adds sophisticated financial expertise that will be crucial for navigating the post-merger integration.
What's most telling about this appointment is that Stamoulis will oversee not just finance but also corporate development initiatives. This expanded scope suggests Mallinckrodt is prioritizing strategic growth through partnerships and M&A following the Endo merger. Given her extensive experience in structuring and executing strategic partnerships, the company appears to be positioning for additional strategic transactions.
CEO Olafsson's characterization of this as a "historic moment" in the company's transformation and the emphasis on "forging a new future" indicates this leadership change is part of a broader strategic pivot. The company is clearly signaling to the market that it has ambitions beyond merely integrating Endo's operations and is actively preparing for its next phase of strategic development.
Ms. Stamoulis will join Mallinckrodt from Incyte, a leading biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. In addition to overseeing the finance organization, she will lead Mallinckrodt's corporate development initiatives, leveraging her deep industry expertise and extensive experience in strategic planning, as well as in originating, structuring, and executing strategic partnerships and M&A transactions.
"We are excited to have Christiana join Mallinckrodt at this historic moment in our transformation," said Siggi Olafsson, Mallinckrodt's President and Chief Executive Officer. "With the completion last week of our merger with Endo, we are forging a new future for our Company and adding talented new leadership to an already strong executive team. Christiana has an exceptional record of achievement in strategy, finance, corporate development, and execution, and we have every expectation that she will make significant contributions to our growth and continued success."
Ms. Stamoulis has approximately 30 years of experience in the biotechnology industry. Prior to Incyte, she was President and CFO of Unum Therapeutics and, before that role, served as Senior Vice President of Corporate Strategy and Business Development at Vertex Pharmaceuticals. Prior to Vertex, Ms. Stamoulis spent nearly 15 years as an investment banker and management consultant, serving as a Managing Director in Citigroup's Investment Banking division and a senior investment banker in the Healthcare Investment Banking Group at Goldman Sachs. She began her career as a strategy consultant at Boston Consulting Group.
"Mallinckrodt has a unique opportunity to reinvent itself following the merger with Endo, and I am honored by the opportunity to join the company at this pivotal point and contribute to the Company's new future," said Ms. Stamoulis.
Ms. Stamoulis currently serves on the Board of Directors of Hologic Inc., a medical technology company. She holds two Bachelor of Science degrees from the Massachusetts Institute of Technology (MIT) and an MBA from the MIT Sloan School of Management.
About Mallinckrodt
Mallinckrodt is a leading provider of life-enhancing therapeutics focused on addressing unmet patient needs and a world-class manufacturer of high-quality generics, sterile injectables, and active pharmaceutical ingredients.
Our company consists of multiple wholly owned subsidiaries that operate in two businesses. Our Brands business is focused on autoimmune and rare diseases in areas including endocrinology, gastroenterology, hepatology, neonatal respiratory critical care, nephrology, neurology, pulmonology, ophthalmology, orthopedics, rheumatology, and urology. Our Par Health business includes generic drugs, sterile injectables, and active pharmaceutical ingredients. To learn more, visit www.MNK-Endo.com.
Mallinckrodt uses its website as a channel of distribution of important company information, such as press releases, investor presentations and other financial information. It also uses its website to expedite public access to time-critical information regarding the Company in advance of or in lieu of distributing a press release or a filing with the U.S. Securities and Exchange Commission ("SEC") disclosing the same information. Therefore, investors should look to the Investor Relations page of the website for important and time-critical information. Visitors to the website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations page of the website.
Contacts
Investors
Juan Avendano
862-240-8194
avendano.juan@endo.com
Media
Michael Freitag / Aura Reinhard / Catherine Simon
Joele Frank, Wilkinson Brimmer Katcher
212-355-4449
Mallinckrodt, the "M" brand mark, the Mallinckrodt Pharmaceuticals logo, Endo and the Endo logo are trademarks owned or licensed by a Mallinckrodt company. Other brands are trademarks of a Mallinckrodt company or their respective owners. © 2025.
View original content to download multimedia:https://www.prnewswire.com/news-releases/mallinckrodt-names-christiana-stamoulis-as-president-and-chief-financial-officer-302522701.html
SOURCE Mallinckrodt plc
FAQ
Who is Mallinckrodt's new CFO and President?
What is Christiana Stamoulis's background and experience?
Why did Mallinckrodt appoint a new CFO?
What will be Christiana Stamoulis's responsibilities at Mallinckrodt?
When will Christiana Stamoulis start at Mallinckrodt (MNK)?
